{"id":188326,"date":"2023-07-26T10:49:38","date_gmt":"2023-07-26T08:49:38","guid":{"rendered":"https:\/\/test.lab.cor2ed.com\/cms\/n-connect\/programmes\/oral-serds-in-er-breast-cancer-episode-3\/"},"modified":"2024-10-25T13:32:29","modified_gmt":"2024-10-25T11:32:29","slug":"oral-serds-breast-cancer-3","status":"publish","type":"programmes","link":"https:\/\/test.lab.cor2ed.com\/cms\/breast-cancer-connect\/programmes\/oral-serds-breast-cancer-3\/","title":{"rendered":"Oral SERDs in ER+ Breast Cancer – Episode 3"},"content":{"rendered":"

In this podcast series, Prof. Shaheenah Dawood<\/strong> and Assoc. Prof. Rena Callahan<\/strong> discuss oral SERDs for ER+\/HER2- advanced or metastatic breast cancer.<\/strong><\/p>\n

\u00a0<\/h3>\n

Episode 1: Oral SERDs in ER+ breast cancer: efficacy, safety and treatment landscape<\/strong><\/h3>\n

The experts explore the efficacy and safety profiles of oral SERDs and their place in the treatment landscape, and discuss how to optimise treatment selection and make appropriate sequencing decisions.<\/p>\n

\u00a0<\/h3>\n

Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond<\/strong><\/h3>\n

A deep-dive into two patient case studies of ER+\/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments.<\/p>\n

\u00a0<\/h3>\n

Episode 3: Oral SERDS in ER+ breast cancer: rare cases & treatment challenges<\/strong><\/h3>\n

Prof. Dawood and Assoc. Prof. Callahan discuss the next two patient case studies of ER+\/HER2- metastatic breast cancer, each presenting unique and rare situations that shed a light on the challenges confronting healthcare professionals and patients alike.<\/p>\n

 <\/p>\n

<\/p>\n

Clinical Takeaways<\/strong><\/h3>\n

 <\/p>\n